<code id='96CDBEEA42'></code><style id='96CDBEEA42'></style>
    • <acronym id='96CDBEEA42'></acronym>
      <center id='96CDBEEA42'><center id='96CDBEEA42'><tfoot id='96CDBEEA42'></tfoot></center><abbr id='96CDBEEA42'><dir id='96CDBEEA42'><tfoot id='96CDBEEA42'></tfoot><noframes id='96CDBEEA42'>

    • <optgroup id='96CDBEEA42'><strike id='96CDBEEA42'><sup id='96CDBEEA42'></sup></strike><code id='96CDBEEA42'></code></optgroup>
        1. <b id='96CDBEEA42'><label id='96CDBEEA42'><select id='96CDBEEA42'><dt id='96CDBEEA42'><span id='96CDBEEA42'></span></dt></select></label></b><u id='96CDBEEA42'></u>
          <i id='96CDBEEA42'><strike id='96CDBEEA42'><tt id='96CDBEEA42'><pre id='96CDBEEA42'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:5398
          he exterior of the U.S. Capitol building is seen at sunrise
          Sarah Silbiger/Getty Images

          WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

          The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

          advertisement

          • One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
          • Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
          • A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

          The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          Discs beat pads, tampons for heavy menstrual flow, new study shows
          Discs beat pads, tampons for heavy menstrual flow, new study shows

          Menstrualdisc,reusablemenstrualeco-friendlyproduct.AdobeTherearemanyperiodproductsonthemarketfrompad

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          What the Wegovy shortage looks like for doctors — and for patients

          Afterphysicallydebilitatingcancertreatment,LaurieBrunnerencounteredanothermedicalhurdle:Shehaddevelo